News & Press
Researchers Detect HERV-W ENV in COVID-19 Patients and Link Expression to Disease Severity
Data published in the Lancet’s EBioMedicine shows that the pathogenic envelope protein of the human endogenous retrovirus W (HERV-W ENV) is found on lymphocytes of hospitalized patients with COVID-19, and that its level of expression is associated with disease severity.
https://geneuro.ch/data/news/GeNeuro-HERV-and-Covid-ENG-April-15-2021.pdf
GeNeuro : financial information for the first quarter 2021
Geneva, Switzerland, April 9, 2021 – 6.00pm CEST
Strong financial situation and visibility:
- Net cash position of €4.8 million
- Debt free
- Company’s operations funded until Q2-2022
GeNeuro Reports 2020 Full-Year Results and Provides Corporate Update
Geneva, Switzerland, April 6, 2021 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a clinical-stage biopharmaceutical company leveraging the biology of human endogenous retroviruses (HERVs) to develop new treatments to stop the progression of neurodegenerative and autoimmune diseases, reported today its full-year results for the year ended December 31, 2020 and provided a corporate update
https://geneuro.ch/data/news/2021.04.06-GeNeuro-PR-FYR2020results-EN-vf.pdf
GeNeuro’s temelimab Phase 2 multiple sclerosis trial cleared to continue following planned Data Safety Monitoring Board Meeting
Geneva, Switzerland, March 2, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the independent Drug Safety Monitoring Board (DSMB) has concluded the Phase 2 trial of temelimab in MS patients should continue as planned without modification. This follows a pre-determined review of the first 8 patients treated with temelimab for 2 months at doses of 18, 36 and 54 mg/kg. The study, called ProTEct-MS, is being conducted at the Karolinska Institutet’s Academic Specialist Center (ASC), in Stockholm (Sweden).
https://geneuro.ch/data/news/GeNeuro-MS-Study-DSMB-Approval-ENG.pdf
GeNeuro completes patient recruitment in temelimab Phase 2 multiple sclerosis trial at the Karolinska Institutet’s Academic Specialist Center (ASC)
Geneva, Switzerland, January 11, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced its cash position at December 31, 2020, issued a business update and provided an outlook on its 2021 activities.
https://geneuro.ch/data/news/PR-GeNeuro-MS-Study-Enrollment-Complete-EN-021821-VF.pdf
GeNeuro receives French state grant to accelerate research into the role of HERV proteins in COVID-19
Geneva, Switzerland, January 26, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced it has received an award from the French national research agency, ANR (Agence Nationale de Recherche), for its COVERI project focused on understanding the role of human endogenous retrovirus (HERV) proteins in the abnormal immune-inflammation or the neurological damages suffered by important subsets of COVID-19 patients.
GeNeuro: Cash position at December 31, 2020, Business Update and Outlook for 2021
Geneva, Switzerland, January 11, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced its cash position at December 31, 2020, issued a business update and provided an outlook on its 2021 activities.
GeNeuro: financial information and business update for the third quarter 2020
Geneva, Switzerland, October 19, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2020 third quarter cash position and issued a business update.
https://geneuro.ch/data/news/GeNeuro-PR-Q3-2020-EN-101920.pdf
GeNeuro Reports 2020 Half-Year Results and Provides Corporate Update
Geneva, Switzerland, September 29, 2020 at 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported its half-year financial results for the period ending June 30, 2020 and provided a corporate update.
https://geneuro.ch/data/news/GeNeuro-PR-1H2020-Results-ENG.pdf
GeNeuro and the Karolinska Institutet’s Academic Specialist Center (ASC) Present Temelimab Neurodegeneration Prevention Study at MSVirtual2020
Geneva, Switzerland, September 14, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that a presentation by Professor Fredrik Piehl of the Karolinska Institutet’s Academic Specialist Center (ASC) at MSVirtual2020 (8th Joint ACTRIMS-ECTRIMS Meeting) provided the rationale and outline on the Phase 2 ProTEct-MS clinical study of temelimab initiated earlier this year.
https://geneuro.ch/data/news/GeNeuro-PR-Presentation-at-8th-ACTRIMS-ECTRIMS-2020-EN-vf.pdf
GeNeuro and the Karolinska Institutet’s Academic Specialist Center (ASC) to Present ProTEct-MS Study of Temelimab at MSVirtual2020
Geneva, Switzerland, September 8, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that the company and the Karolinska Institutet’s Academic Specialist Center (ASC) will present the rationale of its new Phase 2 study at MSVirtual2020 (8th Joint ACTRIMS-ECTRIMS Meeting), held September 11-13, 2020. The trial, which is evaluating the administration of temelimab in patients with relapsing MS to address disease progression independent of relapses following treatment with rituximab, is being conducted at the Karolinska Institutet’s Academic Specialist Center, Stockholm, Sweden.
https://geneuro.ch/data/news/GeNeuro-PR-8th-ACTRIMS-ECTRIMS-2020-eng.pdf
GeNeuro: financial information and business update for the second quarter 2020
Geneva, Switzerland, July 23, 2020, 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today reported on its 2020 second quarter cash position and issued a business update.
https://geneuro.ch/data/news/2020.07.23-GeNeuro-PR-Q2-2020-EN-Final.pdf